Developing new drugs to treat advanced melanoma
Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma
This study is working on developing new treatments for metastatic melanoma, a tough type of skin cancer, by creating special compounds that can stop cancer cells from dividing, which could lead to better and safer options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Middle Tennessee State University NIH-funded |
| Lab location | 1 site (Murfreesboro, United States) |
| Project ID | NIH-10937173 on NIH RePORTER |
What this research studies
This research focuses on creating novel anti-mitotic agents to treat metastatic melanoma, a highly aggressive form of skin cancer with a poor prognosis. The approach involves designing new compounds that can effectively target and inhibit tubulin, a protein essential for cancer cell division. By utilizing advanced molecular modeling and synthetic chemistry, the researchers aim to optimize these compounds to overcome existing treatment limitations, such as drug resistance and toxicity. Patients may benefit from more effective treatment options that could improve survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced metastatic melanoma who have limited treatment options.
Not a fit: Patients with early-stage melanoma or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic melanoma, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in developing novel tubulin inhibitors, indicating that this approach may lead to significant advancements in cancer treatment.
Where this research is happening
Murfreesboro, United States
- Middle Tennessee State University — Murfreesboro, United States (Active)
Researchers
- Principal investigator: Banerjee, Souvik — Middle Tennessee State University
- Study coordinator: Banerjee, Souvik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.